NUDCD1 Antikörper (AA 431-530) (AbBy Fluor® 350)

Produktnummer ABIN6976831

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch NUDCD1 in WB, IF (cc) und IF (p). Er zeigt eine Reaktivität gegenüber Maus.

Kurzübersicht für NUDCD1 Antikörper (AA 431-530) (AbBy Fluor® 350) (ABIN6976831)

Target: NUDCD1 (NudC Domain Containing 1 (NUDCD1))

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser NUDCD1 Antikörper ist konjugiert mit AbBy Fluor® 350

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Produktdetails anti-NUDCD1 Antikörper (AbBy Fluor® 350)

Bindungsspezifität: AA 431-530

Kreuzreaktivität: Maus

Homologie: Human,Rat,Dog,Cow,Sheep,Horse,Rabbit,Zebrafish

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human NUDCD1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu NUDCD1

Target: NUDCD1 (NudC Domain Containing 1 (NUDCD1))

Andere Bezeichnung: NUDCD1

Hintergrund:

Synonyms: 4921532K09Rik, AA407246, AW260430, AW556235, Chronic myelogenous leukemia tumor antigen 66, CML66, CML66 L, FLJ14991, NudC domain containing 1, NudC domain-containing protein 1, NUDC1_HUMAN, nudcd1, OVA66, RGD1310624, Tumor antigen CML66.

Background: The NUDCD1 gene encodes the 583 amino acid CML66 protein which demonstrates expression in a variety of solid tumor cell lines and leukemias. Expression of CML66 in normal tissues is restricted to testis and heart. The CML66 antibody is found in sera of 18-38 % of patients with lung cancer, melanoma or prostate cancer. These findings indicate that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy. A short isoform of CML66, designated CML66-S, is a product of alternative splicing. CML66-S has the same C-terminus as full-lenghth CML66 (also designated CML66-L), but has a unique N-terminus. CML66-S shows predominant expression in testis, and is also expressed in very low levels in tumor cells, while CML66 is expressed in tumor cells and testis.

Gen-ID: 84955

UniProt: Q96RS6